Skip to main content
NVDA-2.15%AAPL+1.33%GOOGL-0.14%MSFT-0.19%AMZN-0.04%TSM-1.84%SPCX+1.81%AVGO-0.20%META-0.07%TSLA-0.22%SKHY-4.72%MU-3.43%BRK-B+0.06%LLY+0.60%JPM-0.43%AMD-2.31%WMT+0.81%V-0.29%XOM-0.46%ASMLa-2.21%JNJ+0.11%INTC-5.28%MA-0.24%0700.HK-1.94%ORCL-2.05%1398.HK+0.79%BAC-0.09%ABBV+0.77%CSCO-0.26%CVX-1.01%COST+0.14%LRCX-3.69%KO+1.14%CAT-0.70%AMAT-1.87%0005.HK-0.78%AP2d-1.11%UNH+0.33%DELL-3.31%HSBA.L-0.98%MS+0.02%PG+0.08%GE+0.44%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.20%HD-0.86%GS-0.13%0939.HK+1.66%NZDJPY-2.67%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.52%GBPJPY-1.47%CADJPY-1.45%EURJPY-1.43%EURNZD+1.28%NZDCAD-1.23%GBPNZD+1.22%NZDUSD-1.18%NZDCHF-1.02%USDNOK+0.96%EURNOK+0.88%CHFNOK+0.85%NOKJPY-0.75%AUDNZD+0.74%USDZAR+0.67%USDSEK+0.61%EURZAR+0.58%USDMXN+0.57%AUDDKK-0.56%AUDCAD-0.54%EURAUD+0.54%EURSEK+0.53%CHFSEK+0.49%GBPZAR+0.49%AUDSGD-0.48%GBPAUD+0.48%AUDUSD-0.45%GBPTRY+0.41%USDTHB+0.38%GBPHKD+0.32%AUDNOK+0.31%NZDSGD-0.29%GBPMXN-0.28%AUDCHF-0.28%USDPLN+0.27%EURCHF+0.24%CADCHF+0.21%GBPCHF+0.20%EURPLN+0.19%USDCHF+0.17%USDSGD+0.17%USDILS+0.16%USDTRY+0.11%EURHKD-0.10%NZDMXN+0.10%USDDKK+0.09%EURSGD+0.08%EURUSD+0.08%PLNJPY-0.06%USDCAD-0.06%GBPUSD+0.05%EURGBP+0.05%EURCZK-0.05%CHFSGD+0.05%SGDJPY+0.05%USDCOP-0.04%USDCNH+0.03%GBPCAD-0.03%EURCNH-0.03%EURCAD+0.02%GBPSGD-0.02%USDHKD0.00%EURDKK0.00%XPTUSD-4.05%HG1-4.03%GAGUSD-3.64%XAGUSD-3.64%UKOIL+1.91%COFFEE-1.84%USOIL+1.73%W1-0.92%COCOA-0.78%GAUUSD-0.64%XAUUSD-0.63%C1-0.56%BTCUSD-1.24%ETHUSD-1.02%USDTUSD-0.06%XRPUSD-1.98%SOLUSD-1.46%TRXUSDT0.00%ZECUSDT-5.46%DOGEUSD-2.43%XMRUSDT-1.64%LINKUSD-0.97%XLMUSD-1.58%BCHUSDT-9.07%LTCUSD-1.45%UNIUSD-3.79%HBARUSDT-1.63%TONUSD+24.88%SUIUSD-2.90%TAOUSDT-4.20%AAVEUSD-2.75%DOTUSDT-3.16%ICPUSDT-0.72%ONDOUSDT-2.53%WLDUSDT-2.43%ATOMUSDT-3.24%ARBUSDT+1.19%JUPUSDT-2.53%INJUSDT-3.51%STXUSDT-3.07%FETUSDT-2.98%TIAUSDT-0.34%PYTHUSDT-0.58%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-2.81%OPUSDT-3.00%IOTAUSDT-3.05%POLUSDT-6.22%AXSUSDT-2.25%FARTCOINUSDT-1.70%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.21%GALAUSDT-3.65%NOTUSDT-1.83%RONINUSDT-2.64%NVDA-2.15%AAPL+1.33%GOOGL-0.14%MSFT-0.19%AMZN-0.04%TSM-1.84%SPCX+1.81%AVGO-0.20%META-0.07%TSLA-0.22%SKHY-4.72%MU-3.43%BRK-B+0.06%LLY+0.60%JPM-0.43%AMD-2.31%WMT+0.81%V-0.29%XOM-0.46%ASMLa-2.21%JNJ+0.11%INTC-5.28%MA-0.24%0700.HK-1.94%ORCL-2.05%1398.HK+0.79%BAC-0.09%ABBV+0.77%CSCO-0.26%CVX-1.01%COST+0.14%LRCX-3.69%KO+1.14%CAT-0.70%AMAT-1.87%0005.HK-0.78%AP2d-1.11%UNH+0.33%DELL-3.31%HSBA.L-0.98%MS+0.02%PG+0.08%GE+0.44%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.20%HD-0.86%GS-0.13%0939.HK+1.66%NZDJPY-2.67%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.52%GBPJPY-1.47%CADJPY-1.45%EURJPY-1.43%EURNZD+1.28%NZDCAD-1.23%GBPNZD+1.22%NZDUSD-1.18%NZDCHF-1.02%USDNOK+0.96%EURNOK+0.88%CHFNOK+0.85%NOKJPY-0.75%AUDNZD+0.74%USDZAR+0.67%USDSEK+0.61%EURZAR+0.58%USDMXN+0.57%AUDDKK-0.56%AUDCAD-0.54%EURAUD+0.54%EURSEK+0.53%CHFSEK+0.49%GBPZAR+0.49%AUDSGD-0.48%GBPAUD+0.48%AUDUSD-0.45%GBPTRY+0.41%USDTHB+0.38%GBPHKD+0.32%AUDNOK+0.31%NZDSGD-0.29%GBPMXN-0.28%AUDCHF-0.28%USDPLN+0.27%EURCHF+0.24%CADCHF+0.21%GBPCHF+0.20%EURPLN+0.19%USDCHF+0.17%USDSGD+0.17%USDILS+0.16%USDTRY+0.11%EURHKD-0.10%NZDMXN+0.10%USDDKK+0.09%EURSGD+0.08%EURUSD+0.08%PLNJPY-0.06%USDCAD-0.06%GBPUSD+0.05%EURGBP+0.05%EURCZK-0.05%CHFSGD+0.05%SGDJPY+0.05%USDCOP-0.04%USDCNH+0.03%GBPCAD-0.03%EURCNH-0.03%EURCAD+0.02%GBPSGD-0.02%USDHKD0.00%EURDKK0.00%XPTUSD-4.05%HG1-4.03%GAGUSD-3.64%XAGUSD-3.64%UKOIL+1.91%COFFEE-1.84%USOIL+1.73%W1-0.92%COCOA-0.78%GAUUSD-0.64%XAUUSD-0.63%C1-0.56%BTCUSD-1.24%ETHUSD-1.02%USDTUSD-0.06%XRPUSD-1.98%SOLUSD-1.46%TRXUSDT0.00%ZECUSDT-5.46%DOGEUSD-2.43%XMRUSDT-1.64%LINKUSD-0.97%XLMUSD-1.58%BCHUSDT-9.07%LTCUSD-1.45%UNIUSD-3.79%HBARUSDT-1.63%TONUSD+24.88%SUIUSD-2.90%TAOUSDT-4.20%AAVEUSD-2.75%DOTUSDT-3.16%ICPUSDT-0.72%ONDOUSDT-2.53%WLDUSDT-2.43%ATOMUSDT-3.24%ARBUSDT+1.19%JUPUSDT-2.53%INJUSDT-3.51%STXUSDT-3.07%FETUSDT-2.98%TIAUSDT-0.34%PYTHUSDT-0.58%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-2.81%OPUSDT-3.00%IOTAUSDT-3.05%POLUSDT-6.22%AXSUSDT-2.25%FARTCOINUSDT-1.70%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.21%GALAUSDT-3.65%NOTUSDT-1.83%RONINUSDT-2.64%
AS

AstraZeneca PLC (AZN)

NYSE • Healthcare

$158.72
+$1.78 (+1.1%)
Market open

September 10, 2026 at 14:29 UTC

Open$158.31
Previous Close$156.94
Day Range$156.74 - $159.13
Avg. Volume (3M)3.3M
Market Cap$243.3B
P/E Ratio23.4
52 Week Range
$146.1$212.71
Next EarningsIn 50 daysOct 30, 2026

Interactive Chart

14:29:59 UTC

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$15.3B100%
Gross Profitminus cost of goods$12.8B84%
Operating Incomeminus R&D and overhead$3.1B21%
Net Incomeminus taxes and the rest$2.5B16%

In plain terms: out of every $100 in revenue, AstraZeneca PLC keeps $16 as net profit.

Fundamentals & Financials

Revenue (TTM)
$61.3B
Net Income (TTM)
$10.4B
EPS (TTM)
$6.72
ROA (TTM)
8.96%
Current Ratio
0.89
Dividend Yield
0.0022%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+1.4%Q1 2026$2.12
+0.4%Q2 2026$2.58
+5.2%Q3 2026$2.63
Next

Oct 30

in 50 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +5.2%

AstraZeneca's adjusted EPS topped consensus while revenue came in just below estimates in the second fiscal quarter of 2026, reported July 27. Revenue rose about 5% to about $15.2 billion from about $14.5 billion a year ago, but it missed the about $15.4 billion consensus by 0.3%, while adjusted EPS of $2.63 topped the $2.50 estimate by 5.2% and was up from $2.18 a year ago. Net income rose about 1% to about $2.5 billion, with gross margin near 74% and operating margin around 20% as operating income reached about $3.1 billion. The company generated operating cash flow of about $2.9 billion and paid $6.3 million in dividends. Consensus for the next period calls for EPS of $2.63 on revenue of $16.07 billion.

View full earnings history

About AstraZeneca PLC

AstraZeneca PLC develops and sells prescription medicines as a large pharmaceutical company listed on the NYSE under AZN, spanning discovery, development, manufacturing, and commercialization. Its portfolio generated $58.7 billion in FY2025 revenue across treatments for cancer, cardiovascular, renal and metabolic conditions, COVID-19, and rare diseases.

Name
AstraZeneca PLC
CEO
Pascal Claude Roland Soriot
Website
www.astrazeneca.com
Industry
Healthcare
Year Founded
1992
Employees
96,100

Today's Snapshot

AI-generated

Yesterday AZN fell 1.9% to 156.94. Deutsche Bank analysts rated AstraZeneca a Sell.

Trading Volume

Above 10d avg 3.2M

3.8M

vs S&P 500 Today

Underperforming Market

-1.46%

Updated: September 10, 2026 at 12:03 UTC

AZN Headlines

FDA clears AstraZeneca breast cancer drug

September 4, 2026

2 min read

AstraZeneca halts key volrustomig lung trial

August 17, 2026

3 min read

AstraZeneca, BMS weigh mega-merger

August 3, 2026

3 min read

Wall St futures rise on Mideast deal hopes

August 3, 2026

3 min read
View All News

Technical Indicators

1 Buy1 Neutral6 Sell
AZN is exhibiting bearish characteristics with the stock trading below its short, medium and long-term moving averages and the pivot positioned above the market price, indicating nearby resistance. Momentum measures are tilted negative—CCI and MACD show selling pressure while RSI is near neutral and stochastic hints at a potential short-term bounce—yet volume on balance is negative. Trend strength is modest rather than strong and volatility is contained. These factors combine to a predominantly negative technical picture. Technical takeaway: Sell — moving averages, momentum and volume favor downside pressure.
All signals
  • EMA (5 indicators)$161.71 - $176.31
    Sell
  • RSI (14)37.81
    Neutral
  • Stochastic %K (14, 3, 3)13.55
    Buy
  • MACD Level (12, 26)-1.63
    Sell

Peers & Related Assets

LLYEli Lilly and Company
$1126.24+0.2%
JNJJohnson & Johnson
$266.79-0.1%
ABBVAbbVie Inc.
$252.1+0.4%
MRKMerck & Co., Inc.
$147.6-0.6%
NVSNovartis AG
$138.87+1.0%
AMGNAmgen Inc.
$386.25-1.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.